Markets:

Overview

News

Currencies

International

Treasuries

Zevra Therapeutics, Inc. - Common Stock (NQ:ZVRA)

8.735 +0.075 (+0.87%)

Streaming Delayed Price Updated: 3:20 PM EST, Dec 5, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Zevra Therapeutics, Inc. - Common Stock

< Previous 1 2 3 Next >

Zevra (ZVRA) Q3 2025 Earnings Call Transcript ↗

November 06, 2025

Zevra (ZVRA) Q3 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Earnings Scheduled For November 5, 2025 ↗

November 05, 2025

Via Benzinga

Top Stocks With Earnings This Week: Joby, IonQ, AMD and More ↗

November 03, 2025

Retail investors are preparing for another busy week of earnings season with more than 1,600 companies set to report through Friday.

Via Benzinga

A Look at Zevra Therapeutics's Upcoming Earnings Report ↗

August 11, 2025

Via Benzinga

Earnings Scheduled For November 12, 2024 ↗

November 12, 2024

Via Benzinga

Beyond The Numbers: 7 Analysts Discuss Zevra Therapeutics Stock ↗

September 24, 2024

Via Benzinga

Zevra Therapeutics' Stock Soars on Strong Performance and Strategic Wins: What It Means for Investors

October 06, 2025

Zevra Therapeutics (NASDAQ: ZVRA) has captured significant attention in the financial markets with its recent robust stock performance and a compelling "Strong" Relative Strength Rating. As of early...

Via MarketMinute

Why PepGen Shares Are Trading Higher By 112%; Here Are 20 Stocks Moving Premarket ↗

September 25, 2025

Shares of PepGen Inc. (NASDAQ: PEPG) rose sharply in pre-market trading after the company announced the launch of an underwritten public offering of common stock and pre-funded warrants.

Via Benzinga

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

September 03, 2025

Via Benzinga

Crude Oil Down 1%; Performance Food Group Earnings Top Views ↗

August 13, 2025

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

August 13, 2025

Via Benzinga

Top movers in Wednesday's session ↗

August 13, 2025

Stay up-to-date with the latest market trends in the middle of the day on Wednesday. Explore the top gainers and losers during today's session in our detailed report.

Via Chartmill

Zevra Reported Its First-Ever Quarterly Profit. Why Shares Of The Top 6% Stock Crashed. ↗

August 13, 2025

Zevra Therapeutics stock gapped down Wednesday after its first-ever quarterly profit missed even more bullish expectations.

Via Investor's Business Daily

Wednesday's session: gap up and gap down stocks ↗

August 13, 2025

Let's have a look at what is happening on the US markets on Wednesday. Below you can find the gap up and gap down stocks in today's session.

Via Chartmill

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

August 13, 2025

Via Benzinga

Zevra Revenue Jumps 486 Percent in Q2 ↗

August 12, 2025

Via The Motley Fool

Topics Intellectual Property

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

August 12, 2025

Via Benzinga

Earnings Scheduled For August 12, 2025 ↗

August 12, 2025

Via Benzinga

How Zevra's Miplyffa Could Transform Investment Strategies ↗

July 02, 2025

HC Wainwright sees Zevra's Miplyffa launch and EU plans driving upside, initiating coverage with a $26 target and Buy rating on rare disease strength.

Via Benzinga

This Block Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday ↗

July 02, 2025

Via Benzinga

Breaking Down Zevra Therapeutics: 6 Analysts Share Their Views ↗

May 14, 2025

Via Benzinga

Zevra Therapeutics (ZVRA) Stock Jumps on Strong Q1 Results: What's Going On? ↗

May 14, 2025

Zevra Therapeutics shares are trading higher by 6.7% Wednesday morning. The company reported better-than-expected Q1 financial results.

Via Benzinga

Zevra Therapeutics's Earnings Outlook ↗

May 12, 2025

Via Benzinga

Earnings Scheduled For May 13, 2025 ↗

May 13, 2025

Via Benzinga

Regulus Downgraded By Analysts After $1.7B Novartis Buyout Offer — Street Sees Limited Upside Ahead ↗

May 01, 2025

Regulus Therapeutics shares surged after Novartis announced a $1.7 billion acquisition, but analysts downgraded the stock citing limited upside. Retail sentiment remained bullish, with speculation of a...

Via Stocktwits

Topics Stocks

Zevra Therapeutics Stock: A Deep Dive Into Analyst Perspectives (5 Ratings) ↗

March 13, 2025

Via Benzinga

Earnings Scheduled For March 11, 2025 ↗

March 11, 2025

Via Benzinga

Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts. ↗

January 09, 2025

Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up.

Via Investor's Business Daily

Topics Artificial Intelligence Government

Zevra Therapeutics' Drug Becomes First FDA-Approved Treatment For Ultra-Rare Neurodegenerative Disease ↗

September 20, 2024

The FDA has approved Zevra Therapeutics' Miplyffa (arimoclomol) as the first treatment for neurological symptoms of Neimann-Pick disease, type C. This approval follows favorable voting by the Genetic...

Via Benzinga

Why Nikola Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

August 19, 2024

Via Benzinga

< Previous 1 2 3 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Oil & Gas Journal starts where other industry publications stop. It delivers more than information; it delivers context, adding details the others leave out and combining them with analysis, commentary, industry trends, and statistics.

Newsletters

The top stories, industry insights and relevant research, assembled by our editors and delivered to your inbox.

Connect

http://www.facebook.com/ogjonline

https://www.linkedin.com/company/oil-&-gas-journal

http://twitter.com/ogjonline

Affiliated Brands

About Us
Advertise
Do Not Sell or Share
Privacy Policy
Terms & Conditions